Perineologic, a subsidiary of Corbin Clinical Resources, Inc., today announced the appointment of Jim Fortune as president, who in this role will be responsible for the company’s business strategy and operations management. Mr. Fortune joins Perineologic with more than 35 years of experience in the medical device industry. Perineologic also announced the promotion of Matthew J. Allaway, DO, to chief executive officer, who previously served as president. Mr. Fortune will report directly to Dr. Allaway.
Perineologic Expands Leadership Team with Appointment of Evan Brasington as Chief Commercial Officer
Perineologic, a subsidiary of Corbin Clinical Resources, Inc., today announced the appointment of Evan Brasington as Chief Commercial Officer. In this role, Mr. Brasington will be a member of the executive leadership team and will lead the company’s commercial strategy including operations, marketing, sales, and distribution of the PrecisionPoint™ Transperineal Access System, the only FDA cleared, CE marked, Class ll medical device for performing freehand transperineal prostate cancer biopsies.
For the past 30 years, screening for prostate-specific antigen (PSA) levels has been the gold standard for screening of prostate cancer. When high levels are found, physicians typically turn to a diagnostic biopsy using a transrectal route. However, a Maryland urologist has developed a different approach through the perineum, the strip of skin between the rectum and scrotum that is safer and more effective.